Business Context and Reporting Period
Company: Alnylam Pharmaceuticals, Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Alnylam is a global commercial-stage biopharmaceutical company developing RNAi therapeutics. The company achieved profitability for the first time in 2025, driven by strong growth in its TTR franchise, particularly AMVUTTRA following its expanded approval for ATTR amyloidosis with cardiomyopathy (ATTR-CM). The company operates under a single segment and has launched the "Alnylam 2030" strategy to expand its pipeline to 10 tissue types and over 40 clinical programs.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenues | $3.71 billion | $2.25 billion | +65% |
| Net Product Revenues | $2.99 billion | $1.65 billion | +81% |
| Net Income (Loss) | $313.7 million | ($278.2 million) | Turnaround to Profit |
| Operating Income (Loss) | $501.6 million | ($176.9 million) | Turnaround to Profit |
| Cash from Operating Activities | $524.1 million | ($8.3 million) | Significant Improvement |
| Cash, Cash Equivalents & Marketable Securities | $2.91 billion | $2.69 billion | +8% |
| Convertible Debt Outstanding | $1.02 billion | $1.04 billion | -2% |
Note: The company reported a provision for income taxes of $9.4 million in 2025 compared to a benefit of $99.2 million in 2024.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 65% year-over-year. Net product revenues surged 81%, primarily driven by AMVUTTRA sales which grew 138% to $2.31 billion, fueled by the March 2025 FDA approval for ATTR-CM. Royalty revenue increased 90% to $174.0 million due to higher Leqvio sales.
- Profitability: The company transitioned from a net loss of $278.2 million in 2024 to a net income of $313.7 million in 2025. Operating income improved from a loss of $176.9 million to $501.6 million.
- Debt Restructuring: In September and December 2025, the company repurchased approximately $672.2 million aggregate principal amount of its 2027 Convertible Senior Notes for a total cost of approximately $1.16 billion. Concurrently, it issued $661.3 million of 0.00% Convertible Senior Notes due 2028.
- Collaboration Milestones: Collaboration revenue increased 8% to $553.4 million, significantly boosted by a $300.0 million milestone payment from Roche in September 2025 for the initiation of the ZENITH Phase 3 trial for zilebesiran.
- Cost Structure: Cost of goods sold increased 121% to $677.2 million, reflecting higher AMVUTTRA sales and associated tiered royalty payments to Sanofi. R&D expenses increased 17% to $1.32 billion due to Phase 3 trial costs for zilebesiran and nucresiran.
Guidance, Outlook, and Risks
Outlook and Strategy
Management launched the "Alnylam 2030" strategy with aspirations to achieve 25%+ total revenue CAGR and ~30% non-GAAP operating margin by 2030. Key growth drivers include the continued commercialization of AMVUTTRA for ATTR-CM globally, the launch of next-generation nucresiran (targeting 2028/2030), and the advancement of zilebesiran for hypertension. The company expects collaboration revenues to decrease in 2026 relative to 2025 due to the one-time $300 million Roche milestone, while royalty revenues are expected to increase.
Risks and Contingencies
- Regulatory and Pricing: The company faces ongoing scrutiny regarding government price reporting. In October 2025, it received a subpoena from the U.S. Attorney's Office for the District of Massachusetts regarding price reporting for AMVUTTRA, ONPATTRO, OXLUMO, and GIVLAARI. Additionally, new executive orders and the Inflation Reduction Act (IRA) pose risks to pricing and reimbursement.
- Competition: AMVUTTRA faces competition in ATTR-CM from oral therapies (tafamidis, acoramidis) and other RNAi/antisense candidates. Leqvio faces potential generic competition following a Paragraph IV certification notice received by Novartis in January 2026.
- Development Risks: The Phase 1 trial of mivelsiran (Alzheimer's/Cerebral Amyloid Angiopathy) remains on partial clinical hold in the U.S. for certain dosing levels. Success of future products depends on clinical trial outcomes and regulatory approvals.
- Liquidity: While the company believes its cash and marketable securities are sufficient for at least 12 months, it carries significant debt obligations, including $1.02 billion in convertible notes and liabilities related to the sale of future royalties (Leqvio) and development funding (Blackstone).
Key Facts for Investor Verification
- AMVUTTRA ATTR-CM Launch: Verify the commercial uptake and market share of AMVUTTRA in the ATTR-CM indication following its March 2025 FDA approval and subsequent global launches.
- Government Investigation: Monitor the outcome of the U.S. Attorney's Office subpoena regarding government price reporting and any potential financial penalties or restatements.
- Debt Obligations: Assess the impact of the $1.48 billion liability related to the sale of future Leqvio royalties and the $175 million milestone payment obligation to Blackstone triggered by AMVUTTRA's ATTR-CM approval.
- Collaboration Milestones: Track the progress of the Roche collaboration (zilebesiran) and Regeneron collaboration (cemdisiran) for future milestone payments and potential revenue recognition.
- Patent Litigation: Review the status of the University of Texas patent infringement lawsuit regarding ONPATTRO, which was transferred to the District of Massachusetts in December 2025.